S100A11 and non-small cell lung carcinoma: We demonstrated the rise in mitochondrial superoxide radical production in cisplatin-treated NSCLC A549 cells upon S100A11 silencing, which was strongly abrogated together with the abolishment of chemosensitization, by NAC, as well as by the PLA2 inhibitor (Fig. 5, 6).